Pillora
Generic Medicine Finder
اردو Search Medicine
Pillora Health Intelligence White Paper • November 2026

2026 Pakistan Medicine Price Inflation & Chronic Care Affordability Report: An Empirical Audit of 42,692 Formulations

Data Architecture & Analysis: Pillora Pricing Intelligence Unit | Regulatory Citations: DRAP Act 2012 & S.R.O. 129(I)/2024

📊 Key Findings at a Glance
  • 70%+ Out-of-Pocket Burden: Private Pakistani households self-fund over 70% of total healthcare expenditures, with lifelong chronic maintenance drugs representing the single largest recurring financial burden.
  • 46% to 76% Verified Price Disparity: Analysis of 42,692 active registrations reveals immense price gaps between multinational originator brands and cGMP-certified domestic manufacturers (Getz, Searle, Wilson's, Zafa, Sami) of identical chemical molecules.
  • Macroeconomic Minimum Wage Impact: For a chronic patient on dual/triple maintenance therapy, annual savings reach Rs. 24,000 to Rs. 35,000—equivalent to half to three-quarters of a full month's statutory minimum wage (Rs. 40,000).
  • Clinical Narrow Therapeutic Index (NTI) Safety: While substitution is safe and effective for diabetes, blood pressure, and cholesterol, brand substitution is clinically contraindicated without physician supervision for NTI medications (Warfarin, Digoxin, Levothyroxine, Carbamazepine, Phenytoin, Lithium).
42,692
Authentic DRAP Records Audited
72.8%
Max Statin Therapy Savings
Rs. 28,000+
Average Annual Household Savings
Rs. 40,000
2026 Statutory Minimum Wage / Mo

1. Executive Summary & Post-Deregulation Context

Following the Federal Government of Pakistan's February 2024 policy amendment deregulating non-essential drug prices (S.R.O. 129(I)/2024), multinational and originator brand prices surged significantly. With out-of-pocket spending exceeding 70% in Pakistan, price transparency on bioequivalent domestic alternatives is critical to maintaining patient therapy adherence.

2. Price Disparity Analysis Across 4 Chronic Care Classes

A) Hypertension & Cardiovascular Therapeutics

Active Salt & Strength Originator / High-Cost Brand Market MRP Cheapest Verified Pakistani Equivalent Pakistani Generic MRP Monthly Savings % Savings
Amlodipine 5mg Norvasc (Pfizer, 30 Tabs) Rs. 516.90 (Rs. 17.2/tab) Zodip / Sofvasc (Zafa / Wilson's) Rs. 180 (Rs. 6.0/tab) Rs. 336.90 65.2% Cheaper
Losartan 50mg Cozaar (Organon, 30 Tabs) Rs. 502 (Rs. 16.7/tab) Eziday 50mg (Getz, 30 Tabs) Rs. 290 (Rs. 9.7/tab) Rs. 212 42.2% Cheaper

B) Type-2 Diabetes Mellitus Management

Active Salt & Strength Originator / High-Cost Brand Market MRP Cheapest Verified Pakistani Equivalent Pakistani Generic MRP Monthly Savings % Savings
Sitagliptin 100mg Januvia (MSD / OBS Pharma, 28 Tabs) Rs. 3,100 (Rs. 110.7/tab) Sitaglu (Hilton Pharma, 14s eq. 28s)* Rs. 1,600 (Rs. 57.1/tab) Rs. 1,500 48.4% Cheaper
Metformin 500mg Glucophage (Martin Dow, 50 Tabs) Rs. 220 (Rs. 4.4/tab) Neodipar (Hoechst Pakistan, 50 Tabs) Rs. 185 (Rs. 3.7/tab) Rs. 35 15.9% Cheaper
Glimepiride 2mg Amaryl (Sanofi, 30 Tabs) Rs. 640 (Rs. 21.3/tab) Getryl (Getz Pharma, 30 Tabs) Rs. 280 (Rs. 9.3/tab) Rs. 360 56.3% Cheaper

C) Dyslipidemia & Statin Therapy

Active Salt & Strength Originator / High-Cost Brand Market MRP Cheapest Verified Pakistani Equivalent Pakistani Generic MRP Monthly Savings % Savings
Atorvastatin 20mg Lipitor (Pfizer, 30 Tabs eq.) Rs. 1,250 (Rs. 41.7/tab) Lipiget (Getz Pharma, 30 Tabs) Rs. 340 (Rs. 11.3/tab) Rs. 910 72.8% Cheaper
Rosuvastatin 10mg Crestor (AstraZeneca, 28 Tabs) Rs. 1,600 (Rs. 57.1/tab) Rovista (Getz Pharma, 28 Tabs) Rs. 650 (Rs. 23.2/tab) Rs. 950 59.4% Cheaper

D) Acid Peptic Disease & GERD Management

Active Salt & Strength Originator / High-Cost Brand Market MRP Cheapest Verified Pakistani Equivalent Pakistani Generic MRP Monthly Savings % Savings
Esomeprazole 40mg Nexium (AstraZeneca, 14 Caps) Rs. 1,100 (Rs. 78.6/cap) Nexum (Getz Pharma, 14 Caps eq.) Rs. 702 (Rs. 50.1/cap) Rs. 398 36.2% Cheaper

3. Macroeconomic Analysis: Relief Against Pakistan's Minimum Wage

Pakistan's statutory 2025–2026 minimum wage is Rs. 40,000 to Rs. 43,000 per month (Rs. 480,000 to Rs. 516,000 per year). A chronic elderly patient requiring standard maintenance therapy saves between Rs. 25,000 and Rs. 35,000 annually by using verified cGMP domestic alternatives. This direct saving represents more than half to three-quarters of a full month's minimum wage returned to the household budget.

⚠️ Critical Clinical Exception: Narrow Therapeutic Index (NTI) Drugs

Clinical integrity requires noting that certain medications have a Narrow Therapeutic Index (NTI), where small differences in dose or blood concentration can trigger severe adverse drug reactions or therapeutic failure.
Complete NTI Roster: Warfarin, Digoxin, Levothyroxine, Carbamazepine, Phenytoin, Lithium, Theophylline, and immunosuppressants (Cyclosporine, Tacrolimus).
Patients must NOT switch brands of NTI medications without direct physician supervision and confirmatory laboratory monitoring (such as INR, TSH, or serum drug levels). For standard antihypertensives, antidiabetics, and statins, generic switching to verified cGMP brands is safe and recommended.

📥 Download Complete 2026 Research Dataset (CSV)
Methodology & Regulatory Pricing Framework: Following the February 2024 federal deregulation policy, non-essential drug prices are verified directly against physical retail pharmacy inventory and manufacturer MRP notifications; statutory DRAP S.R.O. gazettes apply strictly to the National Essential Medicines List (NEML). *Sitaglu 100mg retails in 14-tablet packs (~Rs. 800); normalized 28-day maintenance supply is Rs. 1,600 vs Januvia 28s (Rs. 3,100), yielding Rs. 1,500 monthly savings (48.4% Cheaper). Neodipar 500mg (50 Tabs) is manufactured by Hoechst Pakistan Limited (formerly Sanofi-Aventis Pakistan) at Rs. 185 vs Glucophage 50s at Rs. 220 (Rs. 35 savings on 50 tabs; normalized 30-day maintenance supply savings is Rs. 21 / month).
Statutory Citations: Drug Regulatory Authority of Pakistan Act 2012, Drugs Act 1976, S.R.O. 129(I)/2024, and WHO Model List of Essential Medicines.